- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Vor Biopharma auf dem Citigroup Biopharma-Gipfel: Pipeline-Offensive für Telitacicept | 2 | Investing.com Deutsch | ||
| Di | Vor Bio auf Wells-Fargo-Konferenz: MG-Medikament zielt auf breiten Wirkvorteil ab | 17 | Investing.com Deutsch | ||
| 04.09. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 8 | GlobeNewswire (USA) | ||
| 12.08. | Vor Biopharma reports Q2 results | 2 | Seeking Alpha | ||
| 11.08. | Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 1.517 | GlobeNewswire (Europe) | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen | |
| 11.08. | Vor Biopharma Inc. - 10-Q, Quarterly Report | 7 | SEC Filings | ||
| 03.08. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 07.07. | Vor Bio appoints David Zaccardelli to board of directors | 1 | Investing.com | ||
| 07.07. | Vor Bio beruft erfahrenen Pharma-Manager David Zaccardelli in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 07.07. | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | 275 | GlobeNewswire (Europe) | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| 07.07. | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 08.06. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.06. | Vor Biopharma: Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China | 1 | GlobeNewswire (USA) | ||
| 08.06. | Vor Biopharma: Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China | 643 | GlobeNewswire (Europe) | First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published... ► Artikel lesen | |
| 01.06. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.05. | Vor Biopharma reports Q1 results | 3 | Seeking Alpha | ||
| 13.05. | Vor Biopharma: Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update | 1.019 | GlobeNewswire (Europe) | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen | |
| 13.05. | Vor Biopharma Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade | 5 | Zacks |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,871 | -0,14 % | Valneva: Fortschritte bei Borreliose-Impfstoff geben langfristigem Potenzial Auftrieb | ||
| CRISPR THERAPEUTICS | 45,035 | +1,00 % | Why CRISPR Therapeutics Stock Rocked the Market Last Month | ||
| PALATIN TECHNOLOGIES | 11,600 | -1,69 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,892 | +0,90 % | H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay | ||
| CLINUVEL | 4,982 | -0,64 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| EDITAS MEDICINE | 2,330 | -0,43 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,130 | 0,00 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,740 | +0,57 % | Sarepta Therapeutics climbs 10%, rebounding from recent slide | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -2,05 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| GERON | 1,201 | +3,27 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,644 | 0,00 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,200 | +1,10 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| VERASTEM | 6,362 | +0,57 % | Verastem Stock Skyrockets 121% in 3 Months: Here Is Why | ||
| FATE THERAPEUTICS | 2,054 | -3,30 % | Fate Therapeutics, Inc.: Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 Meeting | SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Resignation of Pad Gopal, Chief Financial Officer and Interim Chief Executive Officer | Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company"), announces that Mr. Pad Gopal has provided... ► Artikel lesen |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,020 (+0,09 %) liegt der Kurs bei 22,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.